Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease

Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.

EP. 1: Background on Graft-vs-Host Disease: Risk Factors and Prevention

March 25th 2022

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

EP. 2: Acute vs Chronic GVHD: Identification and Stratification

March 25th 2022

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

EP. 3: Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

EP. 4: Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

EP. 5: Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

EP. 6: Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

EP. 7: Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

EP. 8: Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

EP. 9: REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

EP. 10: Chronic GVHD: Real-World Use of Ruxolitinib

April 22nd 2022

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.